Literature DB >> 22626807

Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection.

Michelle Wilkison1, Katherine Gauss, Yanchao Ran, Steve Searles, David Taylor, Nicole Meissner.   

Abstract

HIV infection causes loss of CD4(+) T cells and type 1 interferon (IFN)-producing and IFN-responsive dendritic cells, resulting in immunodeficiencies and susceptibility to opportunistic infections, such as Pneumocystis. Osteoporosis and bone marrow failure are additional unexplained complications in HIV-positive patients and patients with AIDS, respectively. We recently demonstrated that mice that lack lymphocytes and IFN a/b receptor (IFrag(-/-)) develop bone marrow failure after Pneumocystis lung infection, whereas lymphocyte-deficient, IFN α/β receptor-competent mice (RAG(-/-)) had normal hematopoiesis. Interestingly, infected IFrag(-/-) mice also exhibited bone fragility, suggesting loss of bone mass. We quantified bone changes and evaluated the potential connection between progressing bone fragility and bone marrow failure after Pneumocystis lung infection in IFrag(-/-) mice. We found that Pneumocystis infection accelerated osteoclastogenesis as bone marrow failure progressed. This finding was consistent with induction of osteoclastogenic factors, including receptor-activated nuclear factor-κB ligand and the proapoptotic factor tumor necrosis factor-related apoptosis-inducing ligand, in conjunction with their shared decoy receptor osteoprotegerin, in the bone marrow of infected IFrag(-/-) mice. Deregulation of this axis has also been observed in HIV-positive individuals. Biphosphonate treatment of IFrag(-/-) mice prevented bone loss and protected loss of hematopoietic precursor cells that maintained activity in vitro but did not prevent loss of mature neutrophils. Together, these data show that bone loss and bone marrow failure are partially linked, which suggests that the deregulation of the receptor-activated nuclear factor-κB ligand/osteoprotegerin/tumor necrosis factor-related apoptosis-inducing ligand axis may connect the two phenotypes in our model.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22626807      PMCID: PMC3388152          DOI: 10.1016/j.ajpath.2012.03.023

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  71 in total

Review 1.  Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease.

Authors:  Nirmal Kaur; Thomas C Mahl
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

Review 2.  Changing global epidemiology of pulmonary manifestations of HIV/AIDS.

Authors:  Mark W Hull; Peter Phillips; Julio S G Montaner
Journal:  Chest       Date:  2008-12       Impact factor: 9.410

Review 3.  Osteoimmunology and the effects of the immune system on bone.

Authors:  Hiroshi Takayanagi
Journal:  Nat Rev Rheumatol       Date:  2009-11-03       Impact factor: 20.543

4.  8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway.

Authors:  Yin Tintut; Farhad Parhami; Anastasia Tsingotjidou; Sotirios Tetradis; Mary Territo; Linda L Demer
Journal:  J Biol Chem       Date:  2002-02-04       Impact factor: 5.157

Review 5.  COPD: a multifactorial systemic disease.

Authors:  Alice Huertas; Paolo Palange
Journal:  Ther Adv Respir Dis       Date:  2011-03-23       Impact factor: 4.031

6.  CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7.

Authors:  Marta Catalfamo; Christopher Wilhelm; Lueng Tcheung; Michael Proschan; Travis Friesen; Jung-Hyun Park; Joseph Adelsberger; Michael Baseler; Frank Maldarelli; Richard Davey; Gregg Roby; Catherine Rehm; Clifford Lane
Journal:  J Immunol       Date:  2011-01-21       Impact factor: 5.422

7.  Prevention of bone marrow cell apoptosis and regulation of hematopoiesis by type I IFNs during systemic responses to pneumocystis lung infection.

Authors:  David Taylor; Michelle Wilkison; Jovanka Voyich; Nicole Meissner
Journal:  J Immunol       Date:  2011-04-06       Impact factor: 5.422

8.  Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients.

Authors:  Michelle K Yong; Julian H Elliott; Ian J Woolley; Jennifer F Hoy
Journal:  J Acquir Immune Defic Syndr       Date:  2011-07-01       Impact factor: 3.731

Review 9.  Osteoporosis and inflammation.

Authors:  Gregory R Mundy
Journal:  Nutr Rev       Date:  2007-12       Impact factor: 7.110

10.  Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice.

Authors:  A G Harmsen; M Stankiewicz
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  7 in total

1.  Type I IFNs Act upon Hematopoietic Progenitors To Protect and Maintain Hematopoiesis during Pneumocystis Lung Infection in Mice.

Authors:  Justin R Prigge; Teri R Hoyt; Erin Dobrinen; Mario R Capecchi; Edward E Schmidt; Nicole Meissner
Journal:  J Immunol       Date:  2015-10-30       Impact factor: 5.422

2.  Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin.

Authors:  E Redondo-Cerezo; F Casado-Caballero; J L Martin-Rodriguez; J Hernandez-Quero; F Escobar-Jimenez; J L Gonzalez-Calvin
Journal:  Osteoporos Int       Date:  2014-03-28       Impact factor: 4.507

3.  B cells modulate systemic responses to Pneumocystis murina lung infection and protect on-demand hematopoiesis via T cell-independent innate mechanisms when type I interferon signaling is absent.

Authors:  Teri R Hoyt; Erin Dobrinen; Irina Kochetkova; Nicole Meissner
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

Review 4.  Neutropenia during HIV infection: adverse consequences and remedies.

Authors:  Xin Shi; Matthew D Sims; Michel M Hanna; Ming Xie; Peter G Gulick; Yong-Hui Zheng; Marc D Basson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2014-03-21       Impact factor: 5.311

5.  Modulation of inflammasome-mediated pulmonary immune activation by type I IFNs protects bone marrow homeostasis during systemic responses to Pneumocystis lung infection.

Authors:  Steve Searles; Katherine Gauss; Michelle Wilkison; Teri R Hoyt; Erin Dobrinen; Nicole Meissner
Journal:  J Immunol       Date:  2013-08-23       Impact factor: 5.422

6.  Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone.

Authors:  Katie L Owen; Linden J Gearing; Damien J Zanker; Natasha K Brockwell; Weng Hua Khoo; Daniel L Roden; Marek Cmero; Stefano Mangiola; Matthew K Hong; Alex J Spurling; Michelle McDonald; Chia-Ling Chan; Anupama Pasam; Ruth J Lyons; Hendrika M Duivenvoorden; Andrew Ryan; Lisa M Butler; John M Mariadason; Tri Giang Phan; Vanessa M Hayes; Shahneen Sandhu; Alexander Swarbrick; Niall M Corcoran; Paul J Hertzog; Peter I Croucher; Chris Hovens; Belinda S Parker
Journal:  EMBO Rep       Date:  2020-04-21       Impact factor: 8.807

Review 7.  Bone effects of biologic drugs in rheumatoid arthritis.

Authors:  Addolorata Corrado; Anna Neve; Nicola Maruotti; Francesco Paolo Cantatore
Journal:  Clin Dev Immunol       Date:  2013-06-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.